Navigation Links
New TB Vaccine Passes Safety Trial
Date:4/8/2009

Experimental preparation was tested in people with latent infection,,

WEDNESDAY, April 8 (HealthDay News) -- An experimental tuberculosis vaccine called MVA85A proved safe in a small phase I clinical trial.

The study included 12 people with latent tuberculosis infection, which, when re-activated, can cause full-blown TB. It's believed that about a third of the world's population has this latent infection. The participants, who had no other complicating factors, such as hepatitis or HIV, were given the vaccine and then followed for a year.

The researchers concluded that the vaccine was safe, did not produce any immunopathology and was immunogenic in the patients. Some participants had side effects that included fever, headache, fatigue and mild concerns at the site of the vaccination.

The findings appear in the April 15 issue of the American Journal of Respiratory and Critical Care Medicine.

This study could be an important step forward in efforts to introduce a new vaccine to fight TB, according to the researchers, led by Dr. Helen McShane, of the University of Oxford in England. They noted that any new vaccine must be developed with latent TB infection in mind because it might decrease the effectiveness of new vaccines or worsen vaccine-related side effects.

"A more effective vaccine regimen than the currently available bacillus Calmette-Guerin would have a major impact on the global TB burden and, ultimately, will be the most efficient way to control this pandemic," the researchers wrote.

They noted that larger trials of the vaccine "are needed in TB endemic areas to assess the efficacy of this vaccine against the development of TB disease, but these results are very encouraging and justify the further development of this vaccine."

More information

The American Lung Association has more about TB.



-- Robert Preidt



SOURCE: American Thoracic Society, news release, April 7, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay
2. Hard To Treat Diseases (HTDS) Offers Hepatitis A Vaccine in India
3. U.S. Adults Needlessly Vulnerable to Vaccine-Preventable Diseases, According to New Report
4. Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis
5. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
6. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
7. Oral Yogurt Vaccine Could Blunt Ouch Factor
8. HPV Data May Aid Vaccines Effectiveness
9. Saving Vaccines with SensoTech's Breakthrough in Vaccine Temperature Monitoring
10. HARD TO TREAT DISEASES (HTDS) Influenca Vaccine (MEVAC-FLU) Enters Chilean Market
11. TB vaccine developed at McMaster University in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New TB Vaccine Passes Safety Trial
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: